Adcock Ingram Holdings Ltd (AIPJ.J)

AIPJ.J on Johannesburg Stock Exchange

5,372.00ZAc
7:26am EDT
Price Change (% chg)

7.00c (+0.13%)
Prev Close
5,365.00c
Open
5,350.00c
Day's High
5,400.00c
Day's Low
5,350.00c
Volume
230,775
Avg. Vol
470,247
52-wk High
7,250.00c
52-wk Low
5,051.00c

AIPJ.J

Chart for AIPJ.J

About

Adcock Ingram Holdings Ltd is a manufacturer, marketer and distributor of healthcare products. The Company is a supplier of hospital and critical care products. Its product portfolio includes branded and generic prescription medicines, over the counter (OTC)/fast moving consumer goods (FMCG) brands, intravenous solutions, blood... (more)

Overall

Beta: 0.56
Market Cap (Mil.): R9,423.34
Shares Outstanding (Mil.): 175.64
Dividend: --
Yield (%): --

Financials

  AIPJ.J Industry Sector
P/E (TTM): 39.54 17.23 33.93
EPS (TTM): 1.36 -- --
ROI: 5.52 9.87 60.26
ROE: 6.29 11.29 66.90
Search Stocks

UPDATE 1-New Adcock boss to overhaul structure of loss-making drugmaker

* Shares fall more than 2 pct (Adds CEO comment, shares)

27 May 2014

South Africa's Adcock swings to first-half loss, halts dividend

JOHANNESBURG, May 27 - South Africa's second-biggest drugmaker Adcock Ingram posted close to a $4 million first-half loss on Tuesday, hit by rising raw materials prices and costs related to a failed $1.2 billion takeover bid from a Chilean suitor.

27 May 2014

BRIEF-Adcock Ingram Holdings H1 gross profit drops 14 pct

* Gross profit for six-month period decreased by 13,9% to r846 million (2013: r983 million)

27 May 2014

South Africa's Adcock flags H1 loss, shares fall

JOHANNESBURG, May 20 - South Africa's No.2 drugmaker, Adcock Ingram Holdings Ltd, flagged a first-half loss on Tuesday, citing costs related to a failed $1.2 billion takeover bid from Chile's CFR Pharmaceuticals .

20 May 2014

BRIEF-Adcock expects H1 headline loss per share of between 22-24 cents

* Shareholders are advised that company is expecting to report a loss per share for interim financial period ended 31 March 2014 of between 24 cents and 25 cents, compared to EPS of 188.0 cents reported for previous comparable six-month period

20 May 2014

UPDATE 1-South Africa's Adcock names industry newcomer as CEO

* New CEO inherits an underperforming company (Adds analyst comment, shares background)

03 Apr 2014

BRIEF-Adcock names Kevin Wakeford as CEO

* Kevin Wakeford has been appointed as chief executive officer of Adcock Ingram with immediate effect Source text for Eikon: Further company coverage:

03 Apr 2014

BRIEF-Adcock says Public Investment Corp's stake totals 25.17 pct

JOHANNESBURG, March 20 - Adcock Ingram Holdings Ltd : * Total of beneficial interests in Adcock Ingram's ordinary shares held by Public Investment Corporation amounts to 25.173 pct

20 Mar 2014

South Africa's Adcock says Q2 profit under "extreme pressure"

JOHANNESBURG, March 19 - South African drugmaker Adcock Ingram Holdings Ltd said quarterly profit was under "extreme pressure" as debt-laden consumers cut back on self-medication and the weaker rand pushed up costs of imported raw materials.

19 Mar 2014

UPDATE 2-CFR drops $1.2 bln bid for S.Africa's Adcock, opening door to rival

JOHANNESBURG, Feb 7 - Chile's CFR Pharmaceuticals dropped a $1.2 billion bid for South Africa's Adcock Ingram on Friday, paving the way for Adcock's largest shareholder to overhaul the underperforming drugmaker.

07 Feb 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$250.00
Provider: MarketLine (a Datamonitor Company)
$50.00
Provider: Directors Deals Ltd.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks